25-Hydroxyvitamin D: Analysis and clinical application

Clinica Chimica Acta

Volumn 433, Issue , 2014, Pages 200-205

  Su, Zengliu ^a   Narla, Satya Nandana ^a   Zhu, Yusheng ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

25 Hydroxyvitamin D; Clinical application; Laboratory analysis

Indexed keywords

25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; VITAMIN D;

ASTHMA; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; COMPETITIVE PROTEIN BINDING ASSAY; DEPRESSION; DIABETES MELLITUS; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MEGADOSE; DRUG OVERDOSE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERVITAMINOSIS; INFECTION; LIQUID CHROMATOGRAPHY; NEOPLASM; NUTRITIONAL REQUIREMENT; OBESITY; OSTEOMALACIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BINDING; RADIOIMMUNOASSAY; RECOMMENDED DRUG DOSE; REVIEW; RICKETS; STANDARDIZATION; TANDEM MASS SPECTROMETRY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; CLINICAL CHEMISTRY; DISEASES; DOSE RESPONSE; METABOLISM; SAFETY;

CLINICAL CHEMISTRY TESTS; DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; SAFETY; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84897935949     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.03.022     Document Type: Review

References (80)

1. Thacher T.D., Clarke B.L. Vitamin D insufficiency. Mayo Clin Proc 2011, 86:50-60.
2. 3 photosynthesis in man: skin pigment is not an essential regulator. Science 1981, 211:590-593.
3. Haddad J.G., Matsuoka L.Y., Hollis B.W., Hu Y.Z., Wortsman J. Human plasma transport of vitamin D after its endogenous synthesis. J Clin Invest 1993, 91:2552-2555.
4. Mundy G.R., Guise T.A. Hormonal control of calcium homeostasis. Clin Chem 1999, 45:1347-1352.
5. 3-1alpha-hydroxylase gene in normocalcemic rats. Proc Natl Acad Sci U S A 1999, 96:8253-8258.
6. Quarles L.D. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res 2012, 318:1040-1048.
7. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:1911-1930.
8. Ross A.C., Manson J.E., Abrams S.A., et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab 2011, 96:53-58.
9. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
10. Wang Y., Zhu J., DeLuca H.F. Where is the vitamin D receptor?. Arch Biochem Biophys 2012, 523:123-133.
11. Pinzone M.R., Di Rosa M., Malaguarnera M., et al. Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. Eur Rev Med Pharmacol Sci 2013, 17:1218-1232.
12. 3 in human monocytes and microphages. Cell Immunol 2012, 280:36-43.
13. 3-dependent regulation of the renin-angiotensin system in 1[alpha]-hydroxylase knockout mice. Kidney Int 2008, 74:170-179.
14. 3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007, 282:29821-29830.
15. Min B. Effects of vitamin D on blood pressure and endothelial function. Korean J Physiol Pharmacol 2013, 17:385-392.
16. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009, 94:26-34.
17. Ingraham B.A., Bragdon B., Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin 2008, 24:139-149.
18. Shah S., Islam M.N., Dakshanamurthy S., et al. The molecular basis of vitamin D receptor and β-catenin crossregulation. Mol Cell 2006, 21:799-809.
19. 3 and its analogs. J Steroid Biochem Mol Biol 2005, 97:137-143.
20. 3-deficient rats. Steroids 1993, 58:335-341.
21. Oh J., Weng S., Felton S.K., et al. 1,25(OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009, 120:687-698.
22. Al Mheid I., Patel R.S., Tangpricha V., Quyyumi A.A. Vitamin D and cardiovascular disease: is the evidence solid?. Eur Heart J 2013, 34:3691-3698.
23. Gardner D.G., Chen S., Glenn D.J. Vitamin D and the heart. Am J Physiol Regul Integr Comp Physiol 2013, 305:R969-R977.
24. Yang C.-Y., Leung P.C., Adamopoulos I., Gershwin M.E. The implication of vitamin D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol 2013, 45:217-226.
25. Agmon-Levin N., Theodor E., Segal R., Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol 2013, 45:256-266.
26. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008, 88:582S-586S.
27. Lips P. Relative value of 25(OH)D and 1,25(OH)2D measurements. J Bone Miner Res 2007, 22:1668-1671.
28. Haddad J.G., Chyu K.J. Competitive protein-binding radioassay for 25-hydroxycholecalciferol. J Clin Endocrinol Metab 1971, 33:992-995.
29. Avioli L.V., Lee S.W. Detection of nanogram quantities of vitamin D by gas-liquid chromatography. Anal Biochem 1966, 16:193-199.
30. 3 by gas-liquid chromatography. Biochem J 1966, 98:293.
31. Warkany J.M.H. Estimation of vitamin D in blood serum: II. Level of vitamin d in human blood serums. Am J Dis Child 1940, 60:606-614.
32. Lensmeyer G.L., Wiebe D.A., Binkley N., Drezner M.K. HPLC method for 25-hydroxyvitamin D measurement: comparison with contemporary assays. Clin Chem 2006, 52:1120-1126.
33. Wallace A.M., Gibson S., de la Hunty A., Lamberg-Allardt C., Ashwell M. Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. Steroids 2010, 75:477-488.
34. 3 by a new binding protein based 25-hydroxyvitamin D assay. Clin Chim Acta 2013, 417:62-66.
35. Hollis B.W., Napoli J.L. Improved radioimmunoassay for vitamin D and its use in assessing vitamin D status. Clin Chem 1985, 31:1815-1819.
36. Hollis B.W. Comparison of commercially available 125I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin Chem 2000, 46:1657-1661.
37. Singh R.J. Are clinical laboratories prepared for accurate testing of 25-hydroxy vitamin D?. Clin Chem 2008, 54:221-223.
38. 3 in human plasma by high-performance liquid chromatography. Clin Chem 1978, 24:287-298.
39. 3 in human serum. Scand J Clin Lab Invest 1992, 52:177-182.
40. 2 analyses. Anal Biochem 2013, 435:1-9.
41. Masuda S.O.T., Kamao M., Kanedai Y., Kobayashi T. A novel high-performance liquid chromatographic assay for vitamin D metabolites using a coulometric electrochemical detector. J Pharm Biomed Anal 1997, 15:1497-1502.
42. Grebe S.K., Singh R.J. LC-MS/MS in the clinical laboratory - where to from here. Clin Biochem Rev 2011, 32:5-31.
43. Fraser W., Milan A. Vitamin D assays: past and present debates, difficulties, and developments. Calcif Tissue Int 2013, 92:118-127.
44. Bouillon R., Van Herck E., Jans I., Tan B.K., Van Baelen H., De Moor P. Two direct (nonchromatographic) assays for 25-hydroxyvitamin D. Clin Chem 1984, 30:1731-1736.
45. 2 by using isotope-dilution liquid chromatography-tandem mass spectrometry. Clin Chem 2011, 57:441-448.
46. 2 in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal Chem 2010, 82:1942-1948.
47. [accessed May 20, 2013]. http://www.bipm.org/jctlm/.
48. Annesley T.M. Ion suppression in mass spectrometry. Clin Chem 2003, 49:1041-1044.
49. Singh R.J., Taylor R.L., Reddy G.S., Grebe S.K.G. C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status. J Clin Endocrinol Metab 2006, 91:3055-3061.
50. Carter G.D., Berry J.L., Gunter E., et al. Proficiency testing of 25-hydroxyvitamin D (25-OHD) assays. J Steroid Biochem Mol Biol 2010, 121:176-179.
51. 2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann Clin Biochem 2006, 43:23-30.
52. Górriz Pintado S., Estela Burriel P.L. Influence of the immunoassay used in measurement of serum vitamin D levels. Endocrinol Nutr 2014, 61:123-129.
53. Holmes E.W., Garbincius J., McKenna K.M. Analytical variability among methods for the measurement of 25-hydroxyvitamin D: still adding to the noise. Am J Clin Pathol 2013, 140:550-560.
54. [accessed May 20, 2013]. http://ods.od.nih.gov/Research/VitaminD.aspx#vdsp.
55. Özkan B., Hatun Ş., Bereket A. Vitamin D intoxication. Turk J Pediatr 2012, 54:93-98.
56. Bell D.A., Crooke M.J., Hay N., Glendenning P. Prolonged vitamin D intoxication: presentation, pathogenesis and progress. Intern Med 2013, 43:1148-1150.
57. Kara C., Gunindi F., Ustyol A., Aydin M. Vitamin D intoxication Due to an erroneously manufactured dietary supplement in seven children. Pediatrics 2014, 133:240-244.
58. Araki T., Holick M.F., Alfonso B.D., et al. Vitamin D intoxication with severe hypercalcemia due to manufacturing and labeling errors of two dietary supplements made in the United States. J Clin Endocrinol Metab 2011, 96:3603-3608.
59. Misra M., Pacaud D., Petryk A., Collett-Solberg P.F., Kappy M. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008, 122:398-417.
60. Krasowski M.D. Pathology consultation on vitamin D testing. Am J Clin Pathol 2011, 136:507-514.
61. Lensmeyer G., Poquette M., Wiebe D., Binkley N. The C-3 epimer of 25-hydroxyvitamin D(3) is present in adult serum. J Clin Endocrinol Metab 2012, 97:163-168.
62. Brehm J.M., Schuemann B., Fuhlbrigge A.L., et al. Childhood Asthma Management Program Research Group. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program Study. J Allergy Clin Immunol 2010, 126:52-58.
63. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
64. Cantorna M.T. Vitamin D and multiple sclerosis: an update. Nutr Rev 2008, 66:S135-S138.
65. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., Giovannucci E., Dietrich T., Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005, 293:2257-2264.
66. Zittermann A., Schleithoff S.S., Tenderich G., Berthold H.K., Korfer R., Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?. J Am Coll Cardiol 2003, 41:105-112.
67. Ginde A.A., Scragg R., Schwartz R.S., Camargo C.A. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc 2009, 57:1595-1603.
68. Dobnig H., Pilz S., Scharnagl H., et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008, 168:1340-1349.
69. Forman J.P., Curhan G.C., Taylor E.N. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 2008, 52:828-832.
70. Jorde R., Figenschau Y., Emaus N., Hutchinson M., Grimnes G. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension 2010, 55:792-798.
71. Garland C.F., Garland F.C., Gorham E.D., Lipkin M., Newmark H., Mohr S. The role of vitamin D in cancer prevention. Am J Public Health 2006, 96:252-261.
72. Lappe J.M., Travers-Gustafson D., Davies K.M., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007, 85:1586-1591.
73. Giovannucci E., Liu Y., Rimm E.B., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006, 98:451-459.
74. Stewart R., Hirani V. Relationship between vitamin D levels and depressive symptoms in older residents from a national survey population. Psychosom Med 2010, 72:608-612.
75. Zipitis C.S., Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008, 93:512-517.
76. Pittas A.G., Chung M., Trikalinos T., et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med 2010, 152:307-314.
77. De Boer I.H., Tinker L.F., Connelly S., et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 2008, 31:701-707.
78. Luong K., Nguyen L.T. Impact of vitamin D in the treatment of tuberculosis. Am J Med Sci 2011, 341:493-498.
79. Yamshchikov A.V., Desai N.S., Blumberg H.M., Ziegler T.R., Tangpricha V. Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr Pract 2009, 15:438-449.
80. Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., Holick M.F. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000, 72:690-693.